KEI KUSHITANI

Last Updated :2025/05/09

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medicine), Assistant Professor
E-mail
kkushihiroshima-u.ac.jp
Other Contact Details
1-2-3，Kasumi，Minami-ku，Hiroshima, Japan
TEL : (+81)82-257-5152 FAX : (+81)82-257-5154
Self-introduction
I am a pathologist who specializes in the pathological diagnosis of respiratory and mediastinal tumors, mainly lung cancer and malignant mesothelioma. I am searching for biomarkers that are useful for lung cancer / mesothelioma diagnosis / treatment / prognosis prediction.

Basic Information

Major Professional Backgrounds

  • 2008/04/01, 2019/03/31, Hiroshima University, Graduate School of Biomedical Sciences, Research associate
  • 2019/04/01, Hiroshima University, Graduate School of Biomedical & Health Sciences, Assistant Professor

Educational Backgrounds

  • Hiroshima University, Japan, 2003/04, 2008/02
  • Hiroshima University, Faculty of Medicine, Japan, 1997/04, 2003/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Biomedical Science
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Biomedical Science
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Basic medicine;Human pathology

Research Keywords

  • Immunohistochemistry
  • Mesothelioma
  • Lung cancer
  • Biomarkers

Affiliated Academic Societies

  • The Japanese Society of Patholigy
    Related URL
  • The Japan Lung Cancer Society
    Related URL
  • The Japanese Society of Clinical Cytology
    Related URL
  • Japan Asbestos Mesothelioma Interest Group

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Second Semester, Clinical Pathology
  2. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2025, Undergraduate Education, 1Term, General Pathology
  4. 2025, Undergraduate Education, 1Term, Pathology
  5. 2025, Undergraduate Education, 1Term, Pathology
  6. 2025, Undergraduate Education, Intensive, Pathology
  7. 2025, Undergraduate Education, 1Term, Outline of Pathology
  8. 2025, Undergraduate Education, Intensive, Outline of Pathology
  9. 2025, Graduate Education (Master's Program) , First Semester, Seminar
  10. 2025, Graduate Education (Master's Program) , Second Semester, Seminar
  11. 2025, Graduate Education (Master's Program) , First Semester, Research
  12. 2025, Graduate Education (Master's Program) , Second Semester, Research
  13. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar
  14. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar
  15. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Research
  16. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Research
  17. 2025, Graduate Education (Master's Program) , Second Semester, Pathologic Basis of Diseases
  18. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Pathology
  19. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Pathology
  20. 2025, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Pathology
  21. 2025, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Pathology

Research Activities

Academic Papers

  1. Reply to "Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma" by Churg et al, AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 48(5), 632-634, 202405
    Link to Paper Search Results by DOI
  2. Utility of Newly Proposed Grading System From International Association for the Study of Lung Cancer for Invasive Lung Adenocarcinoma, JTO CLINICAL AND RESEARCH REPORTS, 2(2), 202102
    Link to Paper Search Results by DOI
  3. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma, AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 48(2), 140-149, 202402
    Link to Paper Search Results by DOI
  4. Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung, CANCERS, 15(23), 202312
    Link to Paper Search Results by DOI
  5. Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion, ANTICANCER RESEARCH, 43(12), 5367-5375, 202312
    Link to Paper Search Results by DOI
  6. miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV, PATHOBIOLOGY, 90(4), 270-280, 202308
    Link to Paper Search Results by DOI
  7. FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling, ANTICANCER RESEARCH, 43(9), 3961-3968, 202309
    Link to Paper Search Results by DOI
  8. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study, LUNG CANCER, 175, 27-35, 202301
    Link to Paper Search Results by DOI
  9. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma, BMC CANCER, 23(1), 20230314
    Link to Paper Search Results by DOI
  10. Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor, DIAGNOSTICS, 12(2), 202202
    Link to Paper Search Results by DOI
  11. Usefulness of serum S100A4 and positron-emission tomography on lung cancer accompanied by interstitial pneumonia, THORACIC CANCER, 14(4), 381-388, 202302
    Link to Paper Search Results by DOI
  12. Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor, Diagnostics (Basel), 12(2), 316, 20220127
  13. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features, ANNALS OF DIAGNOSTIC PATHOLOGY, 60, 202210
    Link to Paper Search Results by DOI
  14. Downregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G(1) cell cycle arrest, ONCOLOGY LETTERS, 23(6), 202206
    Link to Paper Search Results by DOI
  15. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 148(6), 1419-1428, 202206
    Link to Paper Search Results by DOI
  16. Aberrant methylation and loss of expression of O-6-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma, PATHOLOGY INTERNATIONAL, 55(6), 303-309, 200506
    Link to Paper Search Results by DOI
  17. ★, Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma, PATHOLOGY INTERNATIONAL, 57(4), 190-199, 200704
    Link to Paper Search Results by DOI
  18. ★, Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry, PATHOLOGY INTERNATIONAL, 58(2), 75-83, 200802
    Link to Paper Search Results by DOI
  19. ★, A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 130(5), 771-779, 200811
    Link to Paper Search Results by DOI
  20. ★, Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma, HISTOPATHOLOGY, 54(6), 667-676, 200905
    Link to Paper Search Results by DOI
  21. ★, Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma, HISTOPATHOLOGY, 55(1), 10-19, 200907
    Link to Paper Search Results by DOI
  22. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma, ONCOLOGY REPORTS, 24(2), 423-431, 201008
    Link to Paper Search Results by DOI
  23. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines, ONCOLOGY REPORTS, 26(6), 1369-1375, 201112
    Link to Paper Search Results by DOI
  24. Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report, BMC GASTROENTEROLOGY, 12, 20120731
    Link to Paper Search Results by DOI
  25. Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells., Histopathology, 56(7), 969-74, 20100601
  26. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 146(3), 580-585, 201309
    Link to Paper Search Results by DOI
  27. Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 147(6), 1820-1826, 201406
    Link to Paper Search Results by DOI
  28. Prediction for prognosis of resected pT1a-lbN0M0 adenocarcinoma based on tumor size and histological status: Relationship of TNM and IASLC/ATS/ERS classifications, LUNG CANCER, 85(2), 270-275, 201408
    Link to Paper Search Results by DOI
  29. Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 148(4), 1179-1185, 201410
    Link to Paper Search Results by DOI
  30. Letter to the Editor - Reply, PATHOLOGY INTERNATIONAL, 59(4), 274-274, 2009
  31. WIF1 expression is down-regulated by its promoter methylation in mesothelioma, JOURNAL OF THORACIC ONCOLOGY, 4(9), S767-S767, 2009
  32. Pathology of Mesothelioma, Japanese Journal of Lung Cancer, 47(3), 223-232, 20070620
  33. P-317 Gene Expression Analysis of malignant mesothelioma using FFPE samples, Japanese Journal of Lung Cancer, 47(5), 20071010
  34. 19. Caveolin-1 (CAV1) is novel marker of epithelioid mesothelioma (EM) for differentiating it from lung adenocarcinoma (LAC), Japanese Journal of Lung Cancer, 48(4), 353-354, 20080820
  35. O-97 Caveolin-1, a novel marker, differentiates epithelioid mesothelioma from lung adenocarcinoma, Japanese Journal of Lung Cancer, 48(5), 20081005
  36. Evaluation of Apoptosis and Immunohistochemical Expression of the Apoptosis-related Proteins in Mesothelioma, Hiroshima Journal of Medical Sciences, 59(2), 27-33, 20100601
  37. Pleural Biopsy for a Definitive Diagnosis of Malignant Pleural Mesothelioma, JJLC, 50(2), 130-135, 2010
  38. Association between [F-18]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1 alpha and glucose transporter 1 in non-small cell lung cancer, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45(12), 1154-1161, 201512
    Link to Paper Search Results by DOI
  39. ★, Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia, PATHOBIOLOGY, 83(1), 33-40, 2016
    Link to Paper Search Results by DOI
  40. ★, Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma, INTERNATIONAL JOURNAL OF ONCOLOGY, 48(4), 1599-1607, 201604
    Link to Paper Search Results by DOI
  41. 肺乳頭腺腫の1例, 広島県臨床細胞学会誌, 36, 1067-1072, 2015
  42. Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 46(11), 1015-1021, 20160827
    Link to Paper Search Results by DOI
  43. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma, ANNALS OF THORACIC SURGERY, 102(5), 1668-1673, 20160623
    Link to Paper Search Results by DOI
  44. ★, Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma, HISTOPATHOLOGY, 70(3), 375-384, 201702
    Link to Paper Search Results by DOI
  45. ★, PIM1 knockdown inhibits cell proliferation and invasion of mesothelioma cells, INTERNATIONAL JOURNAL OF ONCOLOGY, 50(3), 1029-1034, 201703
    Link to Paper Search Results by DOI
  46. ★, MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma, MODERN PATHOLOGY, 30(5), 672-681, 201705
    Link to Paper Search Results by DOI
  47. ★, Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma, AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 41(8), 1045-1052, 201708
    Link to Paper Search Results by DOI
  48. Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions, HUMAN PATHOLOGY, 66, 177-182, 201708
    Link to Paper Search Results by DOI
  49. ★, MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung, SCIENTIFIC REPORTS, 8, 20180109
    Link to Paper Search Results by DOI
  50. Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing, ONCOTARGET, 8(65), 108936-108945, 20171212
    Link to Paper Search Results by DOI
  51. ★, Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia, ONCOLOGY LETTERS, 15(3), 3540-3547, 201803
    Link to Paper Search Results by DOI
  52. ★, Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma, MODERN PATHOLOGY, 31(5), 809-815, 201805
    Link to Paper Search Results by DOI
  53. Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung, GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 63(3), 153-158, 201503
    Link to Paper Search Results by DOI
  54. The differences in histological changes among pulmonary vessels divided with an energy device, INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 27(3), 372-378, 201809
    Link to Paper Search Results by DOI
  55. ★, miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma, FRONTIERS IN ONCOLOGY, 8, 20181022
    Link to Paper Search Results by DOI
  56. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma, THORACIC CANCER, 9(12), 1594-1602, 201812
    Link to Paper Search Results by DOI
  57. ★, Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma, HISTOPATHOLOGY, 74(4), 545-554, 201903
    Link to Paper Search Results by DOI
  58. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 145(9), 2325-2333, 201909
    Link to Paper Search Results by DOI
  59. Case report of hepatic pseudocyst: A rare manifestation of liver metastasis from an anal squamous cell carcinoma, INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 62, 77-84, 2019
    Link to Paper Search Results by DOI
  60. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component, ANNALS OF SURGICAL ONCOLOGY, 27(3), 945-955, 202003
    Link to Paper Search Results by DOI
  61. Investigation of surgical technique for bronchial stump closure after lobectomy in animal model, GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 68(6), 609-614, 202006
    Link to Paper Search Results by DOI
  62. ★, Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin, ONCOLOGY LETTERS, 19(6), 4161-4168, 202006
    Link to Paper Search Results by DOI
  63. A case of hypomelanotic malignant melanoma in the anus, The Journal of The Hiroshima Medical Association, 72(7), 323-327, 201907
  64. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma, AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 44(9), 1259-1265, 202009
    Link to Paper Search Results by DOI
  65. ★, Pleural Mesothelioma, Pathology and Clinical Medicine, 37(11), 1073-1081, 20191201
  66. Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung, TRANSLATIONAL LUNG CANCER RESEARCH, 10(2), 766-+, 202102
    Link to Paper Search Results by DOI
  67. Primary Small Intestinal Sarcomatoid Carcinoma: Report of a Rare Case and Literature Review, CASE REPORTS IN ONCOLOGY, 14(1), 538-544, 2021
    Link to Paper Search Results by DOI
  68. Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer, BMC PULMONARY MEDICINE, 21(1), 20210602
    Link to Paper Search Results by DOI
  69. Segmentectomy vs. lobectomy for clinical stage IA lung adenocarcinoma with spread through air spaces, The Annals of Thoracic Surgery, 112(3), 935-943, 202109
  70. Bronchial mucosal ablation for bronchial stump closure in right pneumonectomy: a case report, Journal of Medical Case Reports, 15(1), 71-71, 20210218
  71. Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces, ANNALS OF THORACIC SURGERY, 112(3), 935-943, 202109
    Link to Paper Search Results by DOI
  72. Bronchial mucosal ablation for bronchial stump closure in right pneumonectomy: a case report, JOURNAL OF MEDICAL CASE REPORTS, 15(1), 20210218
    Link to Paper Search Results by DOI
  73. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 147(12), 3709-3718, 202112
    Link to Paper Search Results by DOI
  74. Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive size, THORACIC CANCER, 12(23), 3141-3149, 202112
    Link to Paper Search Results by DOI
  75. Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1, ONCOLOGY REPORTS, 47(2), 202202
    Link to Paper Search Results by DOI
  76. Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27(Kip1), FRONTIERS IN ONCOLOGY, 11, 20220119
    Link to Paper Search Results by DOI

Publications such as books

  1. 2007/01, 中皮腫の病理診断のストラテジー--免疫組織化学的染色の有用性, 最新医学, 井内 康輝;武島 幸男;櫛谷 桂
  2. 2008, 中皮腫の病理組織学的鑑別診断に有用な免疫組織化学的染色の検討, [櫛谷桂], 櫛谷桂 [著];櫛谷, 桂
  3. 2007/10/10, P-536 上皮型中皮腫と非腫瘍性中皮細胞の鑑別に有用な免疫組織化学的染色の検討(一般演題(ポスター) 胸膜中皮腫2,第48回日本肺癌学会総会号), 肺癌, 櫛谷 桂;武島 幸男;Amatya VJ;河野 秀和;金 龍男;井内 康輝
  4. 2008/10/05, P-673 上皮型中皮腫と反応性中皮細胞過形成の鑑別診断における抗GLUT-1抗体を用いた免疫組織化学的染色の有用性(悪性中皮腫3,第49回日本肺癌学会総会号), 肺癌, 櫛谷 桂;武島 幸男;Vishwajeet Amatya;金 龍男;河野 秀和;井内 康輝
  5. 2008/10/05, P-672 中皮腫における分泌型Wnt阻害蛋白遺伝子のプロモーター領域のメチル化と蛋白発現の検討-第2報(悪性中皮腫3,第49回日本肺癌学会総会号), 肺癌, 河野 秀和;Jeet Amatya Vishwa;武島 幸男;櫛谷 桂;井内 康輝
  6. 2005/11/05, 肺扁平上皮癌におけるp14, p15, p16遺伝子とMGMT遺伝子のプロモーター領域のメチル化と発生部位による差異(13 癌遺伝子, 第46回 日本肺癌学会総会), 肺癌, 風呂中 修;武島 幸男;櫛谷 桂;坂谷 暁夫;井内 康輝
  7. 2008/08/20, 19. Caveolin-1 (CAV1) is novel marker of epithelioid mesothelioma (EM) for differentiating it from lung adenocarcinoma (LAC), 肺癌, JEET AMATYAVISHWA;河野 秀和;櫛谷 桂;武島 幸男;井内 康輝
  8. 2008/09/22, S2-10 中皮腫病理診断のピットフォール : とくに中皮細胞増殖の良悪性の鑑別(中皮腫の克服を目指して-基礎と臨床の最前線-,グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会), 日本臨床細胞学会雑誌, 井内 康輝;武島 幸男;櫛谷 桂
  9. 2011/05/25, PS-046-2 非小細胞肺癌におけるHIF-1α,Glut-1発現の意義(PS-046 ポスターセッション(46)肺:基礎-2,第111回日本外科学会定期学術集会), 日本外科学会雑誌, 古川 高意;宮田 義浩;津谷 康大;池田 拓広;櫛谷 桂;武島 幸男;井内 康輝;岡田 守人
  10. 2004/10/01, P3-19 原発性肺腺癌の多段階発癌過程におけるEGFR蛋白とHER2蛋白の発現及びCISH法による遺伝子増幅の検討(ポスター総括3 : 病理1 腺癌・その他), 肺癌, 粟屋 浩一;武島 幸男;風呂中 修;櫛谷 桂;井内 康輝
  11. 2008/10/05, O-97 Caveolin-1, a novel marker, differentiates epithelioid mesothelioma from lung adenocarcinoma, 肺癌, Amatya Vishwajeet;武島 幸男;櫛谷 桂;河野 秀和;井内 康輝
  12. 2004/08/20, 54. 肺腺癌におけるMGMT遺伝子のプロモーター領域のメチル化異常と蛋白発現(第43回日本肺癌学会中国四国支部会), 肺癌, 風呂中 修;武島 幸男;粟屋 浩一;櫛谷 桂;井内 康輝
  13. 2006/01/20, 11. 悪性中皮腫の病理診断 : 肺腺癌との鑑別(第15回日本産業衛生学会産業医・産業看護全国協議会, 地方会・研究会記録), 産業衛生学雑誌, 櫛谷 桂;武島 幸男;井内 康輝
  14. 2007/10/10, P-212 中皮腫における分泌型Wnt阻害蛋白遺伝子のプロモーター領域のメチル化と蛋白発現の検討(一般演題(ポスター)22 胸膜中皮腫1,第48回日本肺癌学会総会号), 肺癌, 河野 秀和;Amatya V.j.;櫛谷 桂;武島 幸男;井内 康輝
  15. 2004/08/20, 53. 原発性肺腺癌の多段階発癌過程におけるHER2の蛋白発現及びCISH法による遺伝子増幅の検討(第43回日本肺癌学会中国四国支部会), 肺癌, 粟屋 浩一;武島 幸男;風呂中 修;櫛谷 桂;井内 康輝
  16. 2004/10/01, P9-24 悪性中皮腫の診断に有用な免疫組織化学的染色の検討 : 全国症例を対象として(ポスター総括9 : 外科3 胸膜中皮腫), 肺癌, 櫛谷 桂;武島 幸男;井内 康輝
  17. 2004/10/01, P10-12 非小細胞肺癌におけるMGMT遺伝子のプロモーター領域のメチル化と蛋白発現(ポスター総括10 : 病理2 癌抑制遺伝子・染色体), 肺癌, 風呂中 修;武島 幸男;粟屋 浩一;坂谷 暁夫;櫛谷 桂;井内 康輝
  18. 2007/06/20, 中皮腫の病理, 肺癌, 井内 康輝;武島 幸男;櫛谷 桂
  19. 2005/11/05, 肺癌との鑑別が困難であった肺粘液性腫瘍の一例(29 症例・稀な肺腫瘍1, 第46回 日本肺癌学会総会), 肺癌, 田川 公平;栗栖 佳宏;赤木 真治;加納 幹浩;渡谷 祐介;仁井谷 尚美;櫛谷 桂;武島 幸男
  20. 2007/10/10, P-317 Gene Expression Analysis of malignant mesothelioma using FFPE samples, 肺癌, Amatya Vishwajeet;武島 幸男;河野 秀和;櫛谷 桂;井内 康輝

Invited Lecture, Oral Presentation, Poster Presentation

  1. Gene expression microarray analysis of asbestos-related lung cancer in Japanese patients, Amatya VJ, Kei Kushitani, Yukio Takeshima, 2021/04/22, Without Invitation, Japanese
  2. Musashi-1 is a novel immunohistochemical marker of small cell carcinoma of the lung, 2020/10/01, Without Invitation, English
  3. Alterations of 2p16, 9q33.1 and 19p13 in asbestos-related lung cancer in Japanese patients, 2020/07/01, Without Invitation, English
  4. Musashi-1 is novel immunohistochemical marker of neuroendorine carcinoma of lung, 2019/12/06, Without Invitation, English
  5. Pathological Diagnosis of Lung Cancer, Kei Kushitani, JICA project "The improvement of diagnostic ability in early phase of pneumoconiosis and asbestosis-exposure related respiratory disease", 2019/11/19, Without Invitation, English
  6. Musashi-1 is a novel immunohistochemical marker of small cell carcinoma of lung, 2019/05/09, Without Invitation, English
  7. Pathological Diagnosis of Lung Cancer, Kei Kushitani, JICA project "The improvement of diagnostic ability in early phase of pneumoconiosis and asbestos-related respiratory disease", 2018/12/08, With Invitation, English
  8. miR-182 and miR-183 promote cell proliferation and invasion by targeting FOXO1 in mesothelioma, 2018/11/22, Without Invitation, English
  9. Exploration of the novel immunohistochemical markers of epithelioid mesothelioma and lung adenocarcinoma, 2018/11/22, Without Invitation, English
  10. Glypican-1 is the positive marker to differentiate epithelioid mesothelioma from lung adenocarcinoma, 2018/06/21, Without Invitation, English
  11. Usefulness of Immunohistochemistry in the Differential Diagnosis of Epithelioid Mesothelioma and Lung Squamous Cell Carcinoma, Kei Kushitani, Vishwa Jeet Amatya, Y. Okada, Y. Katayama, A.S. Mawas, Y. Miyata, Morihito Okada, K. Inai, T. Kishimoto, Y. Takeshima, 18th World Conference on Lung Cancer, 2017/10/17, Without Invitation, English, International Association for the Study of Lung Cancer, Yokohama, Japan
  12. Therapeutic Strategies and Genetic Comparisons in SCLC and LCNEC of the Lung Using Next-Generation Sequencing, Masaoki Ito, Y. Miyata, S. Hirano, S. Kimura, F. Irisuna, Kei Kushitani, Yasuhiro Tsutani, Y. Takeshima, Morihito Okada, 18th World Conference on Lung Cancer, 2017/10/17, Without Invitation, English
  13. Diagnostic Utility of MUC4 Expression to Differentiate Epithelioid Mesothelioma from Lung Adenocarcinoma and Squamous Cell Carcinoma, Vishwa Jeet Amatya, A.S. Mawas, Kei Kushitani, Y. Kai, Y. Miyata, Morihito Okada, Y. Takeshima, 18th World Conference on Lung Cancer, 2017/10/16, Without Invitation, English, International Association for the Study of Lung Cancer, Yokohama, Japan
  14. Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma, Masatsugu Kuraoka, Vishwa Jeet Amatya, Kei Kushitani, A.S. Mawas, Y. Miyata, Morihito Okada, T. Kishimoto, K. Inai, T. Nishisaka, T. Sueda, Y. Takeshima, 18th World Conference on Lung Cancer, 2017/10/16, Without Invitation, English, International Association for the Study of Lung Cancer, Yokohama, Japan
  15. MUC4, immunohistochemical marker to differentiate lung adenocarcinoma from epithelioid mesothelioma, Amaya V.J., Kei Kushitani, Rui Suzuki, Mawas A.S., Yukio Takeshima, The 106th Annual Meeting of the Japanese Society of Pathology, 2017/04/27, Without Invitation, English
  16. Utility of intelectin-1 and DAB2 immunostain in distinguishing mesothelioma from lung adenocarcinoma, Kei Kushitani, Amatya Vishwa Jeet, Shin Miyahara, Ikuko Ohoka, Rui Suzuki, Amany Sayed Mawas, Yukio Takeshima, The 106th Annual Meeting of the Japanese Society of Pathology, 2017/04/27, Without Invitation, English
  17. MUC4 is novel markers to differentiate sarcomatoid mesothelioma from sarcomatoid carcinoma of lung, Amatya V.J., Mawas A.S., Kei Kushitani, Yukio Takeshima, 2016/12/19, Without Invitation, English
  18. Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma, Amatya V.J., Mawas A.S., Suzuki R., Kushitani K., Mouchira M. Mohi El-Din, Takeshima Y, Global Academic Program related Meeting between Hiroshima University and the University of Texas MD Anderson Cancer Center, 2016/07/22, Without Invitation, English
  19. Gene expression microarray analysis of sarcomatoid mesothelioma and sarcomatoid carcinoma of lung, 2016/05/12, Without Invitation, English
  20. Functional analysis of PIM-1 expressions in mesothelioma cell lines, 2016/05/12, Without Invitation, English
  21. 肺腫瘤 (Synovial sarcoma), 櫛谷　桂，武島幸男, 第65回広島病理集談会, 2015/12/19, Without Invitation, Japanese
  22. 胸膜中皮腫に対する胸膜切除/肺剥皮術後，同側肺内に発症した原発性肺癌の1例, （斐佑一郎，宮田義浩，鍵本篤志，伊藤正興，津谷康大，三村剛史，櫛谷　桂，武島幸男，岡田守人, 第56回日本肺癌学会学術集会, 2015/11/26, Without Invitation, Japanese, Yokohama
  23. MiR-1, MiR-214 reduces cell proliferation and invasion in mesothelioma cells, Amatya V.J.，Mawas Amany S.，櫛谷　桂，武島幸男, 第56回日本肺癌学会学術集会, 2015/11/26, Without Invitation, Japanese, Yokohama
  24. 肉腫型中皮腫の病理診断における免疫組織化学的染色の有用性と諸問題, 武島幸男，Amatya V.J.，櫛谷　桂, 第22回石綿・中皮腫研究会, 2015/10/31, With Invitation, Japanese
  25. MicroRNA profiling of mesothelioma cell lines & their biological function, Amatya V.J.，Mawas Amany S.，櫛谷　桂，武島幸男, 第22回石綿・中皮腫研究会, 2015/10/31, Without Invitation, Japanese
  26. 胸膜中皮腫に対する胸膜切除/肺剥皮術後，同側肺内に発症した原発性肺癌の1例, 黒川知彰，宮田義浩，鍵本篤志，甲斐佑一郎，伊藤正興，津谷康大，三村剛史，岡田守人，櫛谷　桂，武島幸男, 第109回広島がん治療研究会, 2015/09/19, Without Invitation, Japanese
  27. 肺腫瘤 (Papillary adenoma), 櫛谷　桂，城間紀之，武島幸男, 第64回広島病理集談会, 2015/07/18, Without Invitation, Japanese
  28. A Case of Fetal Lung Interstitial Tumor, Kei Kushitani, Yukio Takeshima, The 104th Annual Meeting of The Japanese Society of Pathology, 2015/05/02, Without Invitation, Japanese, Nagoya
  29. Immunohistochemical analyses of pooly differentiated epithelioid mesothelioma and lung carcinomas, Kei Kushitani, Yuki Naito, Hiroto Shimajiri, Amatya Vishwa Jeet, Yukio Takeshima, The 104th Annual Meeting of The Japanese Society of Pathology, 2015/05/01, Without Invitation, Japanese
  30. Functional analysis of miR-214 transfection on mesothelioma cell lines, Amany S.M.，Amatya V.J.，櫛谷　桂，武島幸男, 2015/04/30, Without Invitation, English
  31. Functional role of mir-1, mir-145, and mir-214 in mesothelioma cell proliferation and invasion, Amatya V.J.，Amany S.M.，塩田大成，森田悟希，櫛谷　桂，武島幸男, 第104回　日本病理学会総会, 2015/04/30, Without Invitation, English
  32. 肺腺癌の間質浸潤部における筋線維芽細胞の増生の意義についての病理組織学的検討, 倉岡正嗣，櫛谷　桂，Amatya V.J.，武島幸男，西阪　隆, 第104回日本病理学会総会, 2015/04/30, Without Invitation, Japanese
  33. 上皮型中皮腫と非小細胞性肺癌（腺癌・扁平上皮癌）の鑑別診断への免疫組織化学的染色の応用, 内藤佑妃，島尻寛人，櫛谷　桂，Amatya V.J.，武島幸男, 第104回日本病理学会総会, 2015/04/30, Without Invitation, Japanese
  34. MiRNA-182, -183 promotes cell growth, invasion, and supresses apoptosis in mesothelioma cells, 2014/11/14, Without Invitation, Japanese
  35. MiRNA-182, -183 promotes cell growth, invasion and suppressed apoptosis in mesothelioma cells, 2014/04/24, Without Invitation, Japanese

Social Activities

History as Peer Reviews of Academic Papers

  1. 2019, Pathology International, Others, Reviewer, 1